Lupus
TheDaoIndex KDAO2011
2 years 9 months ago
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
Mike Putman EBRheum
2 years 9 months ago
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Robert B Chao, MD doctorRBC
2 years 9 months ago
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Eric Dein ericdeinmd
2 years 9 months ago
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.
Abbvie
Poster Hall